Dilapan-S / Dilasoft E-Registry in Induced Abortion

NCT ID: NCT02318212

Last Updated: 2017-05-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

439 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-03-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

International Observational E-Registry on the use of osmotic dilators DILAPAN-S® / DILASOFT® for cervical priming prior to induced abortion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

International, multicentre, non-interventional, observational e-registry, post market clinical follow up study to document current clinical use of Dilapan-S or Dilasoft for cervical priming before induced abortion with regard to the number of dilators used, duration of insertion of dilators in situ and unusual complications consequent of their use.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abortion, Induced

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dilapan-S

Synthetic osmotic dilators Dilapan-S or Dilasoft for cervical priming prior to induced abortion

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dilasoft

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Intrauterine pregnancy ≥ 6 and ≤ 24 weeks gestation
* Patients who are capable of giving consent and sign the form
* Abortion being made in compliance with the Abortion Act 1967 (For England, Wales and Scotland)

Exclusion Criteria

* Clinical signs of uterine, vaginal or vulvar infection
* Acute bleeding
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medicem International CR s.r.o.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Patricia Lohr, MD

Role: PRINCIPAL_INVESTIGATOR

British Pregnancy Advisory Service, UK

Jiri Hanacek, MD

Role: PRINCIPAL_INVESTIGATOR

Institute of Care for Mother and Child, Prague, CZ

Natalia Kan, Prof., MD

Role: PRINCIPAL_INVESTIGATOR

Research Center for Obstetrics, Gynecology and Perinatology, Moscow

John Roizin, MD

Role: PRINCIPAL_INVESTIGATOR

Allentown Women´s Center, Bethlehem, PA, US

Mary Jane Bovo, MD

Role: PRINCIPAL_INVESTIGATOR

Choices Women´s Medical Center, New York

LeRoy Carhart, MD

Role: PRINCIPAL_INVESTIGATOR

Germantown Reproductive Health Service

References

Explore related publications, articles, or registry entries linked to this study.

Allen RH, Goldberg AB; Board of Society of Family Planning. Cervical dilation before first-trimester surgical abortion (<14 weeks' gestation). SFP Guideline 20071. Contraception. 2007 Aug;76(2):139-56. doi: 10.1016/j.contraception.2007.05.001. Epub 2007 Jul 10.

Reference Type BACKGROUND
PMID: 17656184 (View on PubMed)

Fox MC, Krajewski CM. Cervical preparation for second-trimester surgical abortion prior to 20 weeks' gestation: SFP Guideline #2013-4. Contraception. 2014 Feb;89(2):75-84. doi: 10.1016/j.contraception.2013.11.001. Epub 2013 Nov 11.

Reference Type BACKGROUND
PMID: 24331860 (View on PubMed)

Newmann S, Dalve-Endres A, Drey EA; Society of Family Planning. Clinical guidelines. Cervical preparation for surgical abortion from 20 to 24 weeks' gestation. Contraception. 2008 Apr;77(4):308-14. doi: 10.1016/j.contraception.2008.01.004. Epub 2008 Mar 4.

Reference Type BACKGROUND
PMID: 18342657 (View on PubMed)

Schulz KF, Grimes DA, Cates W Jr. Measures to prevent cervical injury during suction curettage abortion. Lancet. 1983 May 28;1(8335):1182-5. doi: 10.1016/s0140-6736(83)92464-9.

Reference Type BACKGROUND
PMID: 6133988 (View on PubMed)

Lichtenberg ES. Complications of osmotic dilators. Obstet Gynecol Surv. 2004 Jul;59(7):528-36. doi: 10.1097/00006254-200407000-00022.

Reference Type BACKGROUND
PMID: 15199271 (View on PubMed)

Samuel MI, Parsons JH. Hygroscopic dilator (Dilapan-S) and misoprostol combination for the early first-trimester termination of pregnancy: a pilot study. J Fam Plann Reprod Health Care. 2009 Jan;35(1):45-7. doi: 10.1783/147118909787072234.

Reference Type BACKGROUND
PMID: 19126319 (View on PubMed)

Chambers DG, Willcourt RJ, Laver AR, Baird JK, Herbert WY. Comparison of Dilapan-S and laminaria for cervical priming before surgical pregnancy termination at 17-22 weeks' gestation. Int J Womens Health. 2011;3:347-52. doi: 10.2147/IJWH.S25551. Epub 2011 Oct 20.

Reference Type BACKGROUND
PMID: 22114527 (View on PubMed)

Chen FC, Bergann A, Krosse J, Merholz A, David M. Isosorbide mononitrate vaginal gel versus misoprostol vaginal gel versus Dilapan-S for cervical ripening before first trimester curettage. Eur J Obstet Gynecol Reprod Biol. 2008 Jun;138(2):176-9. doi: 10.1016/j.ejogrb.2007.09.009. Epub 2007 Nov 5.

Reference Type BACKGROUND
PMID: 17980952 (View on PubMed)

Bartz D, Maurer R, Allen RH, Fortin J, Kuang B, Goldberg AB. Buccal misoprostol compared with synthetic osmotic cervical dilator before surgical abortion: a randomized controlled trial. Obstet Gynecol. 2013 Jul;122(1):57-63. doi: 10.1097/AOG.0b013e3182983889.

Reference Type BACKGROUND
PMID: 23743471 (View on PubMed)

Lyus R, Lohr PA, Taylor J, Morroni C. Outcomes with same-day cervical preparation with Dilapan-S osmotic dilators and vaginal misoprostol before dilatation and evacuation at 18 to 21+6 weeks' gestation. Contraception. 2013 Jan;87(1):71-5. doi: 10.1016/j.contraception.2012.07.006. Epub 2012 Aug 13.

Reference Type BACKGROUND
PMID: 22898362 (View on PubMed)

Poon LC, Parsons J. Audit of the effectiveness of cervical preparation with Dilapan prior to late second-trimester (20-24 weeks) surgical termination of pregnancy. BJOG. 2007 Apr;114(4):485-8. doi: 10.1111/j.1471-0528.2006.01257.x. Epub 2007 Feb 19.

Reference Type BACKGROUND
PMID: 17309543 (View on PubMed)

Newmann SJ, Sokoloff A, Tharyil M, Illangasekare T, Steinauer JE, Drey EA. Same-day synthetic osmotic dilators compared with overnight laminaria before abortion at 14-18 weeks of gestation: a randomized controlled trial. Obstet Gynecol. 2014 Feb;123(2 Pt 1):271-278. doi: 10.1097/AOG.0000000000000080.

Reference Type BACKGROUND
PMID: 24402587 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DIS-2014-010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ulipristal Acetate for Cervical Preparation
NCT03802149 COMPLETED EARLY_PHASE1
Mifepristone vs Misoprostol
NCT06502158 RECRUITING PHASE1